Telcagepant

Telcagepant
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Development terminated;
Pharmacokinetic data
Elimination half-life	5–8 hours
Identifiers
	IUPAC name N-[(3R,6S)-6-(2,3-Difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxamide;
CAS Number	781649-09-0 ;
PubChem CID	11319053;
IUPHAR/BPS	703;
ChemSpider	9494017 ;
UNII	D42O649ALL;
KEGG	D09391 ;
ChEMBL	ChEMBL236593 ;
CompTox Dashboard (EPA)	DTXSID50999410 ;
Chemical and physical data
Formula	C26H27F5N6O3
Molar mass	566.533 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5;
	InChI InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)/t15-,19-/m1/s1 ; Key:CGDZXLJGHVKVIE-DNVCBOLYSA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Telcagepant (INN) (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co.^[1]

In the acute treatment of migraine, it was found to have equal efficacy to rizatriptan^[2] and zolmitriptan.^[3]

A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009, after the "identification of two patients with significant elevations in serum transaminases".^[4] A memo to study locations stated that telcagepant had preliminarily been reported to increase the hepatic liver enzyme alanine transaminase (ALT) levels in "11 out of 660 randomized (double-blinded) study participants." All study participants were told to stop taking the medication.^[5]

In July 2011, Merck announced that it had discontinued development of telcagepant.^[6]

References

^ Molecule of the Month February 2009
^ Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. (April 2008). "Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine". Neurology. 70 (16): 1304–12. doi:10.1212/01.WNL.0000286940.29755.61. PMID 17914062. S2CID 11612471.
^ Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. (December 2008). "Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial". Lancet. 372 (9656): 2115–23. doi:10.1016/S0140-6736(08)61626-8. PMID 19036425. S2CID 43069027.
^ Clinical trial number NCT00797667 for "MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine" at ClinicalTrials.gov
^ Merck & Co.: Memo to all US study locations involved in protocol MK0974-049
^ "Press release: Merck Announces Second Quarter 2011 Financial Results". Merck. July 29, 2011. Archived from the original on April 12, 2013.

[1] Molecule of the Month February 2009

[2] Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. (April 2008). "Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine". Neurology. 70 (16): 1304–12. doi:10.1212/01.WNL.0000286940.29755.61. PMID 17914062. S2CID 11612471.

[3] Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. (December 2008). "Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial". Lancet. 372 (9656): 2115–23. doi:10.1016/S0140-6736(08)61626-8. PMID 19036425. S2CID 43069027.

[4] Clinical trial number NCT00797667 for "MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine" at ClinicalTrials.gov

[5] Merck & Co.: Memo to all US study locations involved in protocol MK0974-049

[6] "Press release: Merck Announces Second Quarter 2011 Financial Results". Merck. July 29, 2011. Archived from the original on April 12, 2013.

[1]

[2]

[3]

[4]

[5]

[6]

See also

References